Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma

Purpose: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Cheng-Wen, Sherman, Bryan, Moore, Lori A., Laethem, Carmen L., Lu, Da-Wen, Pattabiraman, Padmanabhan P., Rao, Ponugoti Vasantha, deLong, Mitchell A., Kopczynski, Casey C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Volume 1: Glaucoma IOP, Neuroprotection and Devices
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963640/
https://www.ncbi.nlm.nih.gov/pubmed/28609185
http://dx.doi.org/10.1089/jop.2017.0023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963640/
https://www.ncbi.nlm.nih.gov/pubmed/28609185
http://dx.doi.org/10.1089/jop.2017.0023

Ejemplares similares